Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LOX | P28300 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4081804 | 0.90 | MAPK8 (0.63) | MAPK8HPGDKMT2ALMNASMN1; SMN2 | |
| SCHEMBL4459782 | 0.89 | MAPK8 (0.53) | MAPK8HPGDKMT2ALMNASMN1; SMN2 | |
| SCHEMBL7307728 | 0.88 | MAPK8 (0.78) | MAPK8HPGDKMT2ALOXLOXL2 | |
| SCHEMBL4086682 | 0.82 | MAPK8 (0.52) | MAPK8HPGDKMT2ALMNASMN1; SMN2 | |
| SCHEMBL4082338 | 0.79 | MAPK8 (0.55) | MAPK8HPGDKMT2ALMNASMN1; SMN2 | |
| SCHEMBL4082313 | 0.77 | MAPK8 (0.53) | MAPK8HPGDKMT2ALMNASMN1; SMN2 | |
| SCHEMBL7310026 | 0.77 | MAPK8 (1.00) | MAPK8 | |
| SCHEMBL4092424 | 0.77 | MAPK8 (0.60) | MAPK8 | |
| SCHEMBL7371941 | 0.76 | MAPK8 (0.65) | MAPK8HPGDKMT2ALMNASMN1; SMN2 | |
| SCHEMBL7319190 | 0.76 | MAPK8 (0.78) | MAPK8HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | JUNG BIRGIT | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BDKRB2, EDNRB, GRK5 | MAPK8 88/4885HPGD 888/4885KMT2A 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.